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Childhood Idiopathic Nephrotic 
Syndrome as a Podocytopathy
Samuel N. Uwaezuoke
Abstract
Idiopathic nephrotic syndrome is the commonest manifestation of glomerular 
disease in children. The syndrome is characterized by massive proteinuria, hypo-
albuminemia, generalized edema, and hyperlipidemia. Although genetic or con-
genital forms are now well recognized, nephrotic syndrome is largely acquired. The 
latter form can be idiopathic or primary (the causes are unknown) and secondary 
(the causes are known renal or non-renal diseases). Idiopathic nephrotic syndrome 
consists of the following glomerulonephritides: minimal change nephropathy 
(MCN), focal segmental glomerulosclerosis (FSGS), membranoproliferative glo-
merulonephritis (MPGN), mesangial proliferative glomerulonephritis (MesPGN), 
and membranous nephritis (MN). The etiopathogenesis of nephrotic syndrome has 
evolved through several hypotheses ranging from immune dysregulation theory and 
increased glomerular permeability theory to the current concept of podocytopathy. 
Podocyte injury is now thought to be the basic pathology in the syndrome. The book 
chapter aims to highlight the mechanisms underlying the pathogenesis of nephrotic 
syndrome as a podocytopathy.
Keywords: idiopathic nephrotic syndrome, glomerular disease, 
glomerulonephritides, podocyte injury
1. Introduction
Nephrotic syndrome is the commonest manifestation of glomerular disease 
which is characterized by massive proteinuria, hypoalbuminemia, generalized 
edema, and hyperlipidemia [1]. In children, primary or idiopathic nephrotic syn-
drome (INS) may be caused by any of these glomerulonephritides: minimal change 
nephropathy (MCN), focal segmental glomerulosclerosis (FSGS), membranopro-
liferative glomerulonephritis (MPGN), mesangial proliferative glomerulonephritis 
(MesPGN), and membranous nephropathy (MN). MCN appears to be the most 
common histopathologic type, followed by FSGS and MPGN in that order [2–4]. 
However, recent reports from different parts of the world suggest a change in the 
pattern of the predominant histopathologic types in childhood INS. For instance, 
there has been a rise in the prevalence rates of FSGS documented among children in 
the West African subregion [5–7]. This trend also applies to MPGN [8], a histological 
subtype hitherto thought to be more common in adult patients.
In the pathogenesis of INS, there is now a paradigm shift from the concept of an 
immune-dysregulated disease of the glomerular basement membrane to that of a 
podocytopathy [9, 10]. In fact, it is now assumed that podocyte abnormalities account 
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for all forms of nephrotic syndrome. Basically, the podocyte is involved in maintain-
ing the structural integrity of the glomerular filtration barrier. Thus, podocyte injury 
and loss result in significant proteinuria as well as progressive glomerulosclerosis 
[11]. Podocytopathy can occur in immunologic and non-immunologic diseases of 
the kidney. Acquired podocytopathies such as MCN and FSGS are considered to have 
immunologic basis [12]. Interestingly, immunosuppressive therapy has been noted 
to directly affect the podocyte through the regulation of interleukin-4 (IL-4) and 
interleukin-13 (IL-13) and several signaling pathways involved with the stabilization 
of the actin cytoskeleton and the distribution of the slit diaphragm components [11]. 
This book chapter aims to discuss the mechanisms underpinning the pathogenesis of 
childhood INS as a podocytopathy.
2. The molecular structure and function of the podocyte
The glomerular filtration barrier is essentially a trilaminate structure which 
consists of the podocyte on the outer surface, the glomerular basement membrane 
(GBM) in the middle, and the fenestrated endothelium on the inner surface 
(Figure 1). The podocyte (also known as the visceral glomerular epithelial cell) 
constitutes the last barrier to protein loss, given its unique structure and location 
as a terminally differentiated cell which lines the outer surface of the GBM. Each 
podocyte comprises the foot processes which are separated by a filtration slit (or the 
slit diaphragm). The foot process comprises components such as actin, myosin-II, 
α-actinin-4, talin, and vinculin which all constitute a contractile structure [13]. 
The filament bundles which make up actin are disposed together as arches between 
contiguous podocyte foot processes [14] and are connected to the GBM at specific 
points through an adhesion molecule (α-3β-1 integrin complex) [15, 16]. Similarly, 
the linkage of the podocyte foot processes to the GBM is made possible through 
both α-3β-1 integrin and dystroglycans [17]. Adjacent foot processes are linked 
by the slit diaphragm, which forms the main size-selective filter barrier in the 
glomerular architecture [18, 19]. The filtration slit is composed of multiple protein 
molecules such as nephrin, P-cadherin, CD2AP, ZO-1, FAT, podocin, and possibly 
Figure 1. 
Schematic representation of the molecular structure of the glomerular filtration barrier (Courtesy: Flickr 
photos).
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Neph1 [20–22]. In addition, synaptopodin is closely related to the actin filaments 
located within the podocyte foot processes [23] and interacts with the tight junction 
protein, MAGI-1, in the same way as α-actinin-4 MAGI-1 being expressed in podo-
cytes as well [24]. The functional integrity of the podocytes depends on the actin 
cytoskeleton. This is critical in preserving the intact glomerular filtration barrier, as 
a healthy podocyte is essential for the maintenance of this barrier.
2.1 The molecular mechanisms in podocytopathy
Among the fundamental biologic events in INS, a molecular disruption of the 
filtration slit or GBM results in proteinuria, while rearrangement of podocyte 
cytoskeleton accounts for foot process effacement. In fact, the basic role played by 
the podocyte actin cytoskeleton (the skeletal structure of the foot processes) in 
the pathogenesis of INS is predicated on the disruption of actin-related proteins 
with the GBM, resulting in effacement of the podocyte foot processes [25]. Still 
at the molecular level, focal adhesion kinase (FAK) plays an essential role in this 
foot process effacement, usually observed in podocytopathies [26]. Furthermore, 
alterations in podocyte proteins such as nephrin and Neph1 (nephrin homologue), 
CD2-associated protein (CD2AP), and podocin all contribute to the pathogenesis 
of INS as podocytopathies [27–29]. Nephrin represents an essential constituent of 
the slit diaphragm and also serves as an efficient mobilizer of other proteins such as 
podocin and CD2AP (Figure 1) [30]. It has been proposed that a vital interaction 
exists between the actin cytoskeleton and the molecules that make up the filtration 
slit such as podocin, nephrin, and CD2AP [31, 32]. Thus, nephrotic-range protein-
uria occurs as a result of structural disruptions in the podocytes which present as 
foot process effacement, as well as changes in the actin cytoskeleton and molecular 
alteration of the filtration slit [33]. Again, the component molecules of the actin 
cytoskeleton include actin, α-actinin, and synaptopodin [34, 35]. Interestingly, 
the upregulation of α-actinin results in the reorganization of the cytoskeleton in 
some nephrotic syndromes [36], while the expression of synaptopodin is gener-
ally preserved in MCN, but diminished in FSGS [37]. Podocalyxin is a molecule 
presumed to mediate the stability of the foot processes [38] and has also been found 
to be raised in nephrotic syndromes [39]. Finally, the fundamental role of adhesion 
molecules such as integrins and focal adhesion proteins has been shown in geneti-
cally based animal experiments which end up in nephrotic syndrome [40, 41]. 
Specifically, α3β1 (the main integrin heterodimer in the podocyte), when destroyed 
in the podocytes of experimental mice, gave rise to nephrotic-range proteinuria and 
foot process effacement. In addition, αvβ3 integrin (also expressed in podocytes) 
can be activated by uroplasminogen type I activator receptor (uPAR) (in podo-
cytes) [42] or its soluble form, suPAR (from the circulation) [43]. Its activation 
notably leads to foot process effacement through the rearrangement of the podocyte 
actin cytoskeleton: a characteristic event in podocytopathy [44].
3. Treatment targets in the podocytopathy model
Interventions targeting molecular pathways which regulate the actin cytoskel-
eton can potentially play an important role in the treatment of proteinuric kidney 
diseases, such as nephrotic syndrome. There are three major molecular frameworks 
which modulate the actin cytoskeleton and prevent podocyte detachment from 
GBM, namely, Rho-GTPases, cell-matrix adhesion proteins, and endocytic proteins. 
For instance, the podocyte-expressed RhoA, Rac1, and Cdc42 regulate signal trans-
duction pathways which affect many aspects of cell behavior, including alterations 
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in the actin cytoskeleton [45, 46]. The regulatory ability of these protein molecules 
on the actin cytoskeleton points to their fundamental role in the pathogenesis of 
nephrotic syndrome and as possible treatment targets [25]. For instance, the inhibi-
tion of RhoA and Rac1 could potentially reduce proteinuria and optimize renal 
function and ameliorate glomerulopathy [47–50], given that elevated RhoA activity 
has been noted to induce foot process effacement and subsequent proteinuria [51].
Furthermore, blocking αvβ3 integrin with an anti-β3 antibody or cilengitide (the 
small molecule inhibitor) was noted to have ameliorated uPAR-induced proteinuria, 
underscoring the importance of this integrin as another potential therapeutic target 
[42, 43]. Also, targeted pharmacologic inhibition of integrin α2β1 in murine models 
also reduced proteinuria [52], while inhibition of major focal adhesion proteins, 
such as FAK and Crk1/Crk2, reduced both podocyte foot process effacement and 
proteinuria [26, 53]. In addition, one important therapeutic target in proteinuria 
is the regulating activation of integrin β1 via abatacept (CTLA-4-Ig) or integrin αv 
inhibitor, cilengitide, or integrin α2β1 [42, 43, 52, 54].
The link between transient receptor potential cation channels (TRPCs) and 
the actin cytoskeleton has also been well reported [25]. TRPCs are nonselective 
cationic channels with affinity for calcium ions, which contribute significantly in 
the pathogenesis of renal and cardiovascular diseases [55]. In podocytes, many 
Potential 
pharmacologic 
agents
Treatment targets 
in podocytopathy
Indications Efficacy Side effects
Cyclosporine A†  
(a major calcineurin 
inhibitor. Another 
example is FK 506)
Downregulation of 
synaptopodin
Clinical use in 
SRNS and in renal 
transplantation
Induces 
remission 
in SRNS
Major side effects in 
humans: tremors, 
hypertension, 
nephrotoxicity, 
hirsutism, and gum 
hypertrophy
Inhibitors of small 
Rho-GTPases‡
Small Rho-
GTPases (Rho A, 
Rac 1)
Still under trial 
(nephrotic 
syndrome)
– –
Cilengitide/anti-β3 
antibody*
Blockage of αvβ3 
integrin
Still under trial 
(nephrotic 
syndrome)
Clinical use in 
glioblastoma
– –
Abatacept Modulating 
activation of 
integrin β1
Still under trial/
clinical use in 
FSGS
– –
Inhibitors of  
TRPC 5**
TRPC 5 Still under trial – –
Bis-T-23 Dynamin 
oligomerization 
and actin 
polymerization
Still under trial 
l (proteinuric 
kidney diseases, 
CKD)
– –
†Protects synaptopodin from cathepsin L-mediated degradation (stabilizes actin cytoskeleton).
‡Potentially ameliorates proteinuria.
*Reduces uroplasminogen type 1 activator receptor-induced proteinuria/also inhibits angiogenesis.
**Protects against liposaccharide-induced proteinuria and foot process effacement (adapted from Ref. [68]).
SRNS, steroid-resistant nephrotic syndrome; CKD, chronic kidney disease; FK 506, nitrogen mustard and tacrolimus; 
FSGS, focal segmental glomerulosclerosis; TRPC, transient receptor potential cation channel
Table 1. 
Summary of current and future treatment targets and the potential drugs for idiopathic nephrotic syndrome.
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TRPCs are reportedly expressed, namely, TRPC1, TRPC3, TRPC4, TRPC5, and 
TRPC6 [56–60]. A striking therapeutic application is the ability of TRPC5 inhibitor 
(ML204) to protect against lipopolysaccharide (LPS)-induced proteinuria, as well 
as protamine sulfate- and LPS-triggered foot process effacement [61].
Regarding the supportive function of synaptopodin on the actin cytoskeleton, 
this protein molecule not only constitutes a linkage to the actin cytoskeleton but 
remains vital for stress fiber synthesis in podocytes [62, 63]. Despite the previ-
ously presumed usefulness of calcineurin inhibitors, like cyclosporine A (CsA) and 
FK506 in the treatment of INS given their immunosuppressive effects on T cells, 
the mediatory role of calcineurin on synaptopodin degradation via induction of 
protease cathepsin L is well established; interestingly, CsA shields synaptopodin 
from cathepsin L-mediated breakdown, thereby maintaining the integrity of the 
actin cytoskeleton [64].
Finally, the regulatory activity of endocytic proteins in the actin cytoskeleton is 
confirmed by recent findings of possible therapeutic benefits of Bis-T-23-induced 
dynamin oligomerization and actin polymerization for nephrotic syndrome [65]. 
In fact, some researchers have shown that the GTPase dynamin is important for 
podocyte physiology [66]. In proteinuric kidney disease, induction of cytoplasmic 
cathepsin L results in degradation of dynamin, ending up with disruption of the 
actin cytoskeleton and proteinuria. Again, the modulating effect of dynamin on the 
actin cytoskeleton is related to the stabilization of the glomerulus. Thus, based on 
the beneficial activity of Bis-T-23 to kidney health in various models of chronic kid-
ney disease (CKD) through the formation of actin-dependent oligomers of dyna-
min and polymers of actin, dynamin has been regarded as a possible therapeutic 
target for the management of CKD [67]. Better still, the recognition of dynamin as 
one of the vital and autonomous regulators of focal adhesion maturation suggests a 
molecular mechanism which underpins the beneficial effect of Bis-T-23 on podocyte 
physiology [67]. The efficacy of some of the therapeutic agents currently used in 
clinical practice and in experimental animal models is summarized in Table 1.
4. Conclusion
Significant progress has now been made in unraveling the complex molecular 
mechanisms and pathways responsible for maintaining podocyte health and thus 
the structural and functional integrity of the glomerular filtration barrier. Podocyte 
injury is now believed to be the basic pathology in childhood INS. As a podocy-
topathy, disruption of the podocyte architecture eventually results in the massive 
proteinuria seen in the syndrome. Consequently, several novel therapeutic targets 
have been proposed and successfully demonstrated, raising hopes for novel phar-
macologic agents which could be useful in treating the disorder.
Glomerulonephritis and Nephrotic Syndrome
6
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Samuel N. Uwaezuoke1,2
1 College of Medicine, University of Nigeria, Ituku-Ozalla Enugu Campus, Nigeria
2 Pediatric Nephrology Firm, University of Nigeria Teaching Hospital, Enugu, 
Nigeria
*Address all correspondence to: snuwaezuoke@yahoo.com; 
samuel.uwaezuoke@unn.edu.ng
7Childhood Idiopathic Nephrotic Syndrome as a Podocytopathy
DOI: http://dx.doi.org/10.5772/intechopen.85994
References
[1] Eddy AA, Symons JM. Nephrotic 
syndrome in childhood. Lancet. 
2003;362:629-639
[2] Churg J, Habib R, White RH. 
Pathology of the nephrotic syndrome in 
children a report for the International 
Study of Kidney Disease in children. 
Lancet. 1970;760:1299-1302
[3] Doe JY, Funk M, Mengel M, 
Doehring E, Ehrich JHH. Nephrotic 
syndrome in African children: Lack 
of evidence for ‘tropical nephrotic 
syndrome’. Nephrology, Dialysis, 
Transplantation. 2006;21:672-676. DOI: 
10.1093/ndt/gfi297
[4] Satgé P, Habib R, Quenum C, 
Boisson ME, Niang I. Particularité. du 
syndrome ne’phrotique chez l’enfant au 
Senegal. Ann Pe’diat. 1970;17:382-393
[5] Asinobi AO, Ademola AD, 
Okolo CA, Yaria JO. Trends in 
the histopathology of childhood 
nephrotic syndrome in Ibadan Nigeria: 
Preponderance of idiopathic focal 
segmental glomerulosclerosis. BMC 
Nephrology. 2015;16:213. DOI: 10.1186/
s12882-015-0208-0
[6] Obiagwu PN, Aliyu A, Atanda 
AT. Nephrotic syndrome among 
children in Kano: A clinicopathological 
study. Nigerian Journal of Clinical 
Practice. 2014;17:370-374. DOI: 
10.4103/1119-3077.130247
[7] Uwaezuoke SN, Okafor HU, Eneh CI, 
Odetunde OI. The triggers and patterns 
of relapse in childhood idiopathic 
nephrotic syndrome: A retrospective, 
descriptive study in a tertiary 
hospital, south-east Nigeria. Journal 
of Clinical Nephrology and Research. 
2016;3(1):1032
[8] Asinobi AO, Gbadegesin RA, 
Adeyemo AA. The predominance 
of membrano-proliferative 
glomerulonephritis in childhood 
nephrotic syndrome in Ibadan. 
West African Journal of Medicine. 
1999;18:203-206
[9] Kaneko K, Tsuji S, Kimata T, et al. 
Pathogenesis of childhood idiopathic 
nephrotic syndrome: A paradigm shift 
from T-cells to podocytes. World Journal 
of Pediatrics. 2015;11:21-28. DOI: 
10.1007/s12519-015-0003-9
[10] Uwaezuoke SN. Pathogenesis of 
idiopathic nephrotic syndrome in 
children: Molecular mechanisms and 
therapeutic implications. Integrative 
Molecular Medicine. 2015;3:484-487. 
DOI: 10.15761/IMM.1000192
[11] Schönenberger E, Ehrich JH, Haller 
H, Schiffer M. The podocyte as a direct 
target of immunosuppressive agents. 
Nephrology, Dialysis, Transplantation. 
2011;26:18-24. DOI: 10.1093/ndt/gfq617
[12] Uwaezuoke SN. Steroid-sensitive 
nephrotic syndrome in children: 
Triggers of relapse and evolving 
hypotheses on pathogenesis. Italian 
Journal of Pediatrics. 2015;41:19. DOI: 
10.1186/s13052-015-0123-9
[13] Drenckhahn D, Franke RP. 
Ultrastructural organization of 
contractile and cytoskeletal proteins 
in glomerular podocytes of chicken, 
rat and man. Laboratory Investigation. 
1988;59:673-682
[14] Mundel P, Kriz W. Structure 
and function of podocytes: An 
update. Anatomy and Embryology. 
1995;192:385-397
[15] Adler S. Characterization of 
glomerular epithelial cell matrix 
receptors. The American Journal of 
Pathology. 1992;141:571-578
[16] Kriedberg JA, Donovan MJ, 
Goldstein SL, Rennke H, Shepherd K, 
Glomerulonephritis and Nephrotic Syndrome
8
Jones RC, et al. Alpha 3 beta 1 integrin 
has a crucial role in kidney and 
lung organogenesis. Development. 
1996;122:3537-3547
[17] Raats CJ, van Den Born J, Baker MA, 
et al. Expression of agrin, dystroglycan, 
and utrophin in normal renal tissue 
and in experimental glomerulopathies. 
The American Journal of Pathology. 
2000;156:1749-1765. DOI: 10.1016/
S0002-9440(10)65046-8
[18] Endlich K, Kriz W, Witzgall R.  
Update in podocyte biology. 
Current Opinion in Nephrology and 
Hypertension. 2001;10:331-340
[19] Tryggvason K, Wartiovaara J.  
Molecular basis of glomerular 
permselectivity. Current Opinion 
in Nephrology and Hypertension. 
2001;10:543-549
[20] Holzman LB, St John PL, Kovari IA, 
et al. Nephrin localizes to the slit pore 
of the glomerular epithelial cell. Kidney 
International. 1999;56:1481-1491
[21] Schwarz K, Simons M, Reiser J,  
et al. Podocin, a raft-associated 
component of the glomerular slit 
diaphragm, interacts with CD2AP 
and nephrin. The Journal of Clinical 
Investigation. 2001;108:1621-1629. DOI: 
10.1172/JCI12849
[22] Inoue T, Yaoita E, Kurihara H, et al. 
FAT is a component of glomerular slit 
diaphragms. Kidney International. 
2001;59:1003-1012
[23] Mundel P, Gilbert P, Kriz W. 
Podocytes in glomerulus of rat kidney 
express a characteristic 44KD protein. 
The Journal of Histochemistry and 
Cytochemistry. 1991;39:1047-1056
[24] Patrie KM, Drescher AJ, Welihinda 
A, Mundel P, Margolis B. Interaction 
of two actin-binding proteins, 
synaptopodin and alpha-actinin-4, 
with the tight junction protein MAGI-1. 
The Journal of Biological Chemistry. 
2002;277:30183-30190
[25] Tian X, Ishibe S. Targeting 
the podocyte cytoskeleton: From 
pathogenesis to therapy in proteinuric 
kidney disease. Nephrology, Dialysis, 
Transplantation. 2016;31:1577-1583. 
DOI: 10.1093/ndt/gfw021
[26] Ma H, Togawa A, Soda K, et al. 
Inhibition of podocyte FAK protects 
against proteinuria and foot process 
effacement. Journal of the American 
Society of Nephrology. 2010;21:1145-1156. 
DOI: 10.1681/ASN.2009090991
[27] Donoviel DB, Freed DD, Vogel 
H, et al. Proteinuria and perinatal 
lethality in mice lacking NEPH1, 
a novel protein with homology to 
NEPHRIN. Molecular and Cellular 
Biology. 2001;21:4829-4836. DOI: 
10.1128/MCB.21.14.4829-4836.2001
[28] Shaw AS, Miner JH. CD2-associated 
protein and the kidney. Current Opinion 
in Nephrology and Hypertension. 
2001;10:19-22
[29] Boute N, Gribouval O, Roselli S, 
et al. NPHS2, encoding the glomerular 
protein podocin, is mutated in 
autosomal recessive steroid-resistant 
nephrotic syndrome. Nature Genetics. 
2000;24:349-354. DOI: 10.1038/74166
[30] Patrakka J, Tryggvason K. Nephrin: 
A unique structural and signaling 
protein of the kidney filter. Trends in 
Molecular Medicine. 2007;13:396-403. 
DOI: 10.1016/j.molmed.2007.06.006
[31] Yuan H, Takeuchi E, Salant DJ. 
Podocyte slit-diaphragm protein 
nephrin is linked to the actin 
cytoskeleton. American Journal 
of Physiology. Renal Physiology. 
2002;282:F585-F591. DOI: 10.1152/
ajprenal.00290.2001
[32] Lehtonen S, Zhao F, Lehtonen E.  
CD2-associated protein directly 
9Childhood Idiopathic Nephrotic Syndrome as a Podocytopathy
DOI: http://dx.doi.org/10.5772/intechopen.85994
interacts with the actin cytoskeleton. 
American Journal of Physiology. Renal 
Physiology. 2002;283:F734-F743. DOI: 
10.1152/ajprenal.00312.2001
[33] Somlo S, Mundel P. Getting a 
foothold in nephrotic syndrome. 
Nature Genetics. 2000;24:333-335. DOI: 
10.1038/74139
[34] Andrews PM. Investigations of 
cytoplasmic contractile and cytoskeletal 
elements in the kidney glomerulus. 
Kidney International. 1981;20:549-562
[35] Mundel P, Heid HW, Mundel TM, 
et al. Synaptopodin: An actin-associated 
protein in telencephalic dendrites and 
renal podocytes. The Journal of Cell 
Biology. 1997;139:193-204
[36] Smoyer WE, Mundel P, Gupta 
A, Welsh MJ. Podocyte alpha-actinin 
induction precedes foot process 
effacement in experimental nephrotic 
syndrome. The American Journal of 
Physiology. 1997;273:F150-F157
[37] Srivastava T, Garola RE, 
Whiting JM, Alon US. Synaptopodin 
expression in idiopathic nephrotic 
syndrome of childhood. Kidney 
International. 2001;59:118-125. DOI: 
10.1046/j.1523-1755.2001.00472.x
[38] Kerjaschki D, Sharkey DJ, Farquhar 
MG. Identification and characterization 
of podocalyxin—The major sialoprotein 
of the renal glomerular epithelial 
cell. The Journal of Cell Biology. 
1984;98:1591-1596
[39] Kavoura E, Gakiopoulou 
H, Paraskevakou H, et al. 
Immunohistochemical evaluation 
of podocalyxin expression in 
glomerulopathies associated with 
nephrotic syndrome. Human Pathology. 
2011;42:227-235. DOI: 10.1016/j.
humpath.2010.05.028
[40] Pozzi A, Jarad G, Moeckel GW, et al. 
Beta1 integrin expression by podocytes 
is required to maintain glomerular 
structural integrity. Developmental 
Biology. 2008;316:288-301. DOI: 
10.1016/j.ydbio.2008.01.022
[41] Kanasaki K, Kanda Y, Palmsten K,  
et al. Integrin beta1-mediated 
matrix assembly and signaling are 
critical for the normal development 
and function of the kidney 
glomerulus. Developmental Biology. 
2008;313:584-593
[42] Wei C, Möller CC, Altintas MM, 
et al. Modification of kidney barrier 
function by the urokinase receptor. 
Nature Medicine. 2008;14:55-63. DOI: 
10.1038/nm1696
[43] Wei C, El Hindi S, Li J, et al. 
Circulating urokinase receptor as a cause 
of focal segmental glomerulosclerosis. 
Nature Medicine. 2011;17:952-960. DOI: 
10.1038/nm.2411
[44] Lin Y, Rao J, Zha XL, Xu H. 
Angiopoietin-like 3 induces podocyte 
F-actin rearrangement through 
integrin α (V) β₃/FAK/PI3K pathway-
mediated Rac1 activation. BioMed 
Research International. vol 2013; 
Article ID 135608, 8 pages. DOI: 
10.1155/2013/135608
[45] Pertz O, Hodgson L, Klemke RL, 
Hahn KM. Spatiotemporal dynamics of 
RhoA activity in migrating cells. Nature. 
2006;440:1069-1072. DOI: 10.1038/
nature04665
[46] Heasman SJ, Ridley AJ. 
Mammalian Rho GTPases: New 
insights into their functions from 
in vivo studies. Nature Reviews. 
Molecular Cell Biology. 2008;9:690-701. 
DOI: 10.1038/nrm2476
[47] Babelova A, Jansen F, Sander K, 
et al. Activation of Rac-1 and RhoA 
contributes to podocyte injury in 
chronic kidney disease. PLoS One. 
2013;8:(11):e80328. DOI: 10.1371/
journal.pone.0080328
Glomerulonephritis and Nephrotic Syndrome
10
[48] Hidaka T, Suzuki Y, Yamashita 
M, et al. Amelioration of crescentic 
glomerulonephritis by RhoA kinase 
inhibitor, Fasudil, through podocyte 
protection and prevention of leukocyte 
migration. The American Journal of 
Pathology. 2008;172:603-614
[49] Shikawa Y, Nishikimi T, Akimoto 
K, et al. Long-term administration of 
rho-kinase inhibitor ameliorates renal 
damage in malignant hypertensive rats. 
Hypertension. 2006;47:1075-1083. DOI: 
10.1161/01.HYP.0000221605.94532.71
[50] Sun GP, Kohno M, Guo P, et al. 
Involvements of Rho-kinase and TGF-beta 
pathways in aldosterone-induced renal 
injury. Journal of the American Society 
of Nephrology. 2006;17:2193-2201. DOI: 
10.1681/ASN. 2005121375
[51] Wang L, Ellis MJ, Gomez JA, et al. 
Mechanisms of the proteinuria induced 
by Rho GTPases. Kidney International. 
2012;81:1075-1085. DOI: 10.1038/
ki.2011.472
[52] Borza CM, Su Y, Chen X, et al. 
Inhibition of integrin α2β1 ameliorates 
glomerular injury. Journal of the 
American Society of Nephrology. 
2012;23:1027-1038
[53] George B, Verma R, Soofi AA, 
Garg P, Zhang J, Park TJ, et al. Crk1/2-
dependent signaling is necessary for 
podocyte foot process spreading in 
mouse models of glomerular disease. 
The Journal of Clinical Investigation. 
2012;122:674-692. DOI: 10.1172/
JCI60070
[54] Yu CC, Fornoni A, Weins A, et al. 
Abatacept in B7-1-positive proteinuric 
kidney disease. The New England Journal 
of Medicine. 2013;369:2416-2423. DOI: 
10.1056/NEJMoa1304572
[55] Abramowitz J, Birnbaumer L. 
Physiology and pathophysiology of 
canonical transient receptor potential 
channels. The FASEB Journal. 
2009;23:297-328. DOI: 10.1096/
fj.08-119495
[56] Goel M, Sinkins WG, Zuo CD, 
Estacion M, Schilling WP. Identification 
and localization of TRPC channels 
in the rat kidney. American Journal 
of Physiology. Renal Physiology. 
2006;290:F1241-F1252. DOI: 10.1152/
ajprenal.00376.2005
[57] Dryer SE, Reiser J. TRPC6 channels 
and their binding partners in podocytes: 
Role in glomerular filtration and 
pathophysiology. American Journal 
of Physiology. Renal Physiology. 
2010;299:689-701. DOI: 10.1152/
ajprenal. 00298.2010
[58] Kalwa H, Storch U, Demleitner 
J, et al. Phospholipase C epsilon 
(PLCε) induced TRPC6 activation: A 
common but redundant mechanism in 
primary podocytes. Journal of Cellular 
Physiology. 2015;230:1389-1399. DOI: 
10.1002/jcp.24883
[59] Ilatovskaya DV, Levchenko V, 
Ryan RP, Cowley AW Jr, Staruschenko 
A. NSAIDs acutely inhibit TRPC 
channels in freshly isolated rat 
glomeruli. Biochemical and 
Biophysical Research Communications. 
2011;408:242-247. DOI: 10.1016/j.
bbrc.2011.04.005
[60] Kim EY, Alvarez-Baron CP, Dryer 
SE. Canonical transient receptor 
potential channel (TRPC) 3 and TRPC6 
associate with large-conductance 
Ca2+-activated K+ (BKCa) channels: 
Role in BKCa trafficking to the surface 
of cultured podocytes. Molecular 
Pharmacology. 2009;75:466-477. DOI: 
10.1124/mol.108.051912
[61] Schaldecker T, Kim S, Tarabanis 
C, et al. Inhibition of the TRPC5 ion 
channel protects the kidney filter. 
The Journal of Clinical Investigation. 
2013;123:5298-5309. DOI: 10.1172/
JCI71165
11
Childhood Idiopathic Nephrotic Syndrome as a Podocytopathy
DOI: http://dx.doi.org/10.5772/intechopen.85994
[62] Asanuma K, Kim K, Oh J, et al. 
Synaptopodin regulates the actin-
bundling activity of alpha-actinin 
in an isoform-specific manner. The 
Journal of Clinical Investigation. 
2005;115:1188-1198. DOI: 10.1172/
JCI23371
[63] Asanuma K, Yanagida-Asanuma E, 
Faul C, et al. Synaptopodin orchestrates 
actin organization and cell motility via 
regulation of RhoA signaling. Nature 
Cell Biology. 2006;8:485-491. DOI: 
10.1038/ncb1400
[64] Faul C, Donnelly M, Merscher-
Gomez S, et al. The actin cytoskeleton of 
kidney podocytes is a direct target of the 
antiproteinuric effect of cyclosporine 
A. Nature Medicine. 2008;14:931-938. 
DOI: 10.1038/nm.1857
[65] Schiffer M, Teng B, Gu C, et al. 
Pharmacological targeting of actin-
dependent dynamin oligomerization 
ameliorates chronic kidney disease 
in diverse animal models. Nature 
Medicine. 2015;21:601-609. DOI: 
10.1038/nm.3843
[66] Sever S, Altintas MM, Nankoe 
SR, et al. Proteolytic processing of 
dynamin by cytoplasmic cathepsin 
L is a mechanism for proteinuric 
kidney disease. The Journal of Clinical 
Investigation. 2007;117:2095-2104. DOI: 
10.1172/JCI32022
[67] Gu C, Lee HW, Garborcauskas G, 
Reiser J, Gupta V, Sever S. Dynamin 
autonomously regulates podocyte 
focal adhesion maturation. Journal of 
the American Society of Nephrology. 
2017;28:446-451. DOI: 10.1681/
ASN.2016010008
[68] Uwaezuoke SN. Childhood 
idiopathic nephrotic syndrome as a 
podocytopathy: Potential therapeutic 
targets. Journal of Clinical Nephrology 
and Research. 2017;4(4):1071
